UP 421
Alternative Names: HIP-modified primary islet cells - Sana Biotechnology; UP-421Latest Information Update: 05 Mar 2024
At a glance
- Originator Sana Biotechnology
- Class Antihyperglycaemics; Gene therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Type 1 diabetes mellitus
Most Recent Events
- 29 Feb 2024 Phase-I clinical trials in Type 1 diabetes mellitus in Sweden (IM) prior to February 2024 (NCT06239636)
- 29 Feb 2024 Pharmacodynamics data from preclinical studies in Type 1 diabetes mellitus released by Sana Biotechnology
- 17 Nov 2023 Swedish Medical Products Agency approves CTA application for UP 421 in Type 1 diabetes mellitus